Becton, Dickinson and Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas E. Polen Jr.
- Full Time Employees
- 72,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1 Becton Drive Franklin Lakes NJ United States of America 07417-1880
- IPO Date
- Feb 21, 1973
- CIK
- 0000010795
- Website
- bd.com
- Similar Companies
- Business
- Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.
Company News
BDX DCF Analysis: Intrinsic Value $157 vs Price $187
Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends
Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”
BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
BD to Present at Wells Fargo 21st Annual Healthcare Conference
BDX DCF Analysis: Intrinsic Value $157 vs Price $190
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing
BDX DCF Analysis: Intrinsic Value $141 vs Price $181
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value
We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures
Becton, Dickinson and Company Q3 Earnings Call Highlights
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates